4th Quarter - Report

PARRY, ROMANI, DECONCINI & SYMMS for BRAIDWOOD MANAGEMENT, INC.

Firm
Client
Income
$10,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

LobbyistCovered position, as disclosed
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S.Con.Res. 88 (110th), H.Con.Res. 342 (110th)

Pharmacy PHA

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

LobbyistCovered position, as disclosed
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 342 (110th), S.Con.Res. 88 (110th)

Medical/Disease Research/Clinical Labs MED

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

LobbyistCovered position, as disclosed
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 342 (110th), S.Con.Res. 88 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.